Normal (n = 31) | Â | Â | Â | Â |
---|---|---|---|---|
Category | Â | Training (n = 10) | Validation (n = 21) | p-value |
Age (y) | Â | Â | Â | 0.5400* |
 | Mean | 55.80 | 57.81 |  |
 | Median | 55.00 | 55.00 |  |
 | Max | 75.00 | 80.00 |  |
 | Min | 44.00 | 46.00 |  |
Gender | Â | Â | Â | N/A |
 | Female | 20 | 68 |  |
 | Male | 0 | 0 |  |
Race |  |  |  | 0.2216†|
 | White | 9 | 14 |  |
 | Other | 1 | 7 |  |
BI-RADS Score |  |  |  | 0.2540‡ |
 | 0 | 0 | 2 |  |
 | 1 | 9 | 13 |  |
 | 2 | 1 | 6 |  |
 | 3 | 0 | 0 |  |
 | 4 | 0 | 0 |  |
 | 5 | 0 | 0 |  |
 | 6 | 0 | 0 |  |
 | Incomplete/Unavailable | 0 | 0 |  |
Malignant (n = 57) | Â | Â | Â | Â |
Category | Â | Training (n = 10) | Validation (n = 47) | p-value |
Age (y) | Â | Â | Â | 0.6444* |
 | Mean | 61.4 | 58.68 |  |
 | Median | 56 | 61 |  |
 | Max | 85 | 85 |  |
 | Min | 43 | 32 |  |
Gender | Â | Â | Â | N/A |
 | Female | 10 | 47 |  |
 | Male | 0 | 0 |  |
Race |  |  |  | 1.0000†|
 | White | 9 | 14 |  |
 | Other | 1 | 7 |  |
BI-RADS Score |  |  |  | 0.8695‡ |
 | 0 | 0 | 2 |  |
 | 1 | 0 | 2 |  |
 | 2 | 1 | 2 |  |
 | 3 | 0 | 0 |  |
 | 4 | 3 | 16 |  |
 | 5 | 4 | 12 |  |
 | 6 | 0 | 2 |  |
 | Incomplete/Unavailable | 2 | 11 |  |
HER2 |  |  |  | 0.2253‡ |
 | Positive | 3 | 5 |  |
 | Negative | 4 | 18 |  |
 | Unknown | 3 | 24 |  |
ER |  |  |  | 0.1036‡ |
 | 0 - 2 | 3 | 15 |  |
 | 3 - 8 | 4 | 6 |  |
 | Unknown | 3 | 26 |  |
PR |  |  |  | 0.2844‡ |
 | 0 - 2 | 4 | 12 |  |
 | 3 - 8 | 3 | 8 |  |
 | Unknown | 3 | 27 |  |
Positive Lymph Nodes |  |  |  | 0.0685‡ |
 | No LN Sampling | 1 | 23 |  |
 | 0 | 5 | 18 |  |
 | 1 | 1 | 4 |  |
 | 2 | 1 | 1 |  |
 | 3 | 0 | 1 |  |
 | 9 | 1 | 0 |  |